About [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium
[2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium (PubChem CID 159943587) has the molecular formula C41H68N5O2S+
and a molecular weight of 695.10 g/mol. Its IUPAC name is [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium.
Molecular Properties
| Compound Name | [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium |
| PubChem CID | 159943587 |
| Molecular Formula | C41H68N5O2S+ |
| Molecular Weight | 695.10 g/mol |
| Exact Mass | 694.51 |
| IUPAC Name | [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium |
| SMILES | CCCCCCCCCCCC/[N+](CC)=C1\C=NC(=C2C(=O)C(c3cnc(N(CCCCCCCC)CCCCCCCC)cn3)=C2O)S1 |
| InChI | InChI=1S/C41H67N5O2S/c1-5-9-12-15-18-19-20-21-24-25-28-45(8-4)36-33-44-41(49-36)38-39(47)37(40(38)48)34-31-43-35(32-42-34)46(29-26-22-16-13-10-6-2)30-27-23-17-14-11-7-3/h31-33H,5-30H2,1-4H3/p+1 |
| InChIKey | CPJNDDFMOXSXTC-UHFFFAOYSA-O |
| XLogP | 11.24 |
| TPSA | 81.69 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 28 |
| Heavy Atoms | 49 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
| MW ≤ 500 | 695.10 |
| LogP ≤ 5 | 11.24 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'}, {'alert_name': 'imine_1', 'substructure': 'N/A'}, {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'}, {'alert_name': 'quaternary_nitrogen_1', 'substructure': 'N/A'} |
|---|
Analyze [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium with MolForge
Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.
Launch Full Analysis
Frequently Asked Questions
What is the IUPAC name of [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium?
The IUPAC name of [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium (CID 159943587) is [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium.
What is the SMILES notation for [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium?
The canonical SMILES for [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium is CCCCCCCCCCCC/[N+](CC)=C1\C=NC(=C2C(=O)C(c3cnc(N(CCCCCCCC)CCCCCCCC)cn3)=C2O)S1.
What is the InChIKey of [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium?
The InChIKey is CPJNDDFMOXSXTC-UHFFFAOYSA-O. The full InChI is InChI=1S/C41H67N5O2S/c1-5-9-12-15-18-19-20-21-24-25-28-45(8-4)36-33-44-41(49-36)38-39(47)37(40(38)48)34-31-43-35(32-42-34)46(29-26-22-16-13-10-6-2)30-27-23-17-14-11-7-3/h31-33H,5-30H2,1-4H3/p+1.
What are the key properties of [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium?
[2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium has a molecular weight of 695.10 g/mol, XLogP of 11.24, 28 rotatable bonds, 1 hydrogen bond donors, and 7 hydrogen bond acceptors.
Where does this data come from?
All data for [2-[3-[5-(dioctylamino)pyrazin-2-yl]-2-hydroxy-4-oxocyclobut-2-en-1-ylidene]-1,3-thiazol-5-ylidene]-dodecyl-ethylazanium is sourced from PubChem (CID 159943587), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).